BioMimetic Recieves FDA Approval
BioMimetic Therapeutics (BMTI) announced early Friday that the company has recieved FDA approval of the facility established for manufacturing rhPDGF-BB, the key compound in the company's periodontal bone defect product GEM 21S.
GEM 21S was approved for marketing in the US in 2005 and in Canada in 2006.
This news release followed two days of interesting trading of the company's stock. On October 11 the stock jumped on 7x average daily volume with no significant news.
_
BioMimetic Therapeutics (BMTI) announced early Friday that the company has recieved FDA approval of the facility established for manufacturing rhPDGF-BB, the key compound in the company's periodontal bone defect product GEM 21S.
GEM 21S was approved for marketing in the US in 2005 and in Canada in 2006.
This news release followed two days of interesting trading of the company's stock. On October 11 the stock jumped on 7x average daily volume with no significant news.
_
posted by Nico at
8:38 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home